Navigation Links
EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Date:4/22/2008

o develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director, Corpo
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
2. EntreMed Receives Nasdaq Deficiency Notice
3. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
4. EntreMed Announces 2008 Corporate and Clinical Program Priorities
5. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
6. EntreMed to Present at BIO CEO and Investor Conference
7. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
8. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
9. EntreMed Appoints Senior Vice President of Research and Development
10. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
11. Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... The 6th Annual Arrowhead Personalized and ... 29-30 in San Francisco, CA. This year’s conference brings ... and clinicians focused on addressing and solving the significant ... twelve years since the sequencing of the human genome, ... pharmacogenetic information in the label and molecular diagnostics have ...
(Date:8/20/2014)... 2014 WriteResult®, a leading provider of ... has expanded its myPROpad™ ePRO tablet with the addition ... of the most widely used and well-respected Patient Reported ... The EQ-5D is used during clinical trials and in ... can be used to demonstrate Health-Related Quality of Life ...
(Date:8/19/2014)... , Aug. 19, 2014 Research and Markets  has ... - Global Strategic Business Report" report to their offering. ... Tissue Culture Supplies in US$ Thousands by the following Product Segments: ... analytics for the US, Canada , ... , and Latin America . Annual estimates ...
(Date:8/19/2014)... August 19, 2014 Robin Williams’ passing ... can take on an individual. Symptoms range from ... expression, problems swallowing and severe depression. Parkinson’s disease ... off of dopamine producing neurons of the brain. ... disease that slowly and progressively gets worse, they look ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2EQ-5D™ Assessment Now Available for iPad 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3
... In a visit to the Menomonee Valley, Gov. Jim ... his 2007-09 state budget for the new Wisconsin Venture Center. ... sector partnership that will connect entrepreneurs with sources of capital, ... seeking deals in Wisconsin. , ,The concept was announced in ...
... - Wisconsin officials and investors who are trying to ... life science firm to relocate here have a fight on ... willing to let go of Aruna Biomedical , an ... researchers and is seeking to move from research to production. ...
... Strong, who has served as vice president of ... appointed president and chief operating officer of the Madison-based ... the company's board of directors and announced at the ... chemistry degree from the University of Wisconsin-Madison , ...
Cached Biology Technology:Doyle proposes $2M for venture capital center 2Wisconsin won't get Georgia biotech without a fight 2Wisconsin won't get Georgia biotech without a fight 3
(Date:8/20/2014)... by researchers at the University of Missouri School of ... life-threatening heart condition caused by muscular dystrophy. , ... Ph.D., the leading author of the study and assistant ... of Molecular Microbiology and Immunology. "This is just a ... a treatment for people with this devastating heart condition, ...
(Date:8/20/2014)... absorbs light and its energy is finally utilized ... Photovoltaic devices, mostly build from silicon based semiconductors, ... approach for the development of cheaper and renewable ... isolated membrane protein complexes of photosynthesis. Prof. Dr. ... from thermophilic cyanobacteria that live in a hot ...
(Date:8/19/2014)... China,s increasing caesarean section rate, suggests a new commentary ... Journal of Obstetrics and Gynaecology (BJOG) . , China ... the world. Of 16 million babies born in 2010, ... is not known, the current Chinese language literature on ... from 36% to 58%. However, before the 1980s, the ...
Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2A semi-artificial leaf faster than 'natural' photosynthesis 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3
... traditional practice in animal testing has been standardization, but ... as few as two controlled environmental variables to preclinical ... number of animals needed for testing and the cost ... assistant professor of animal sciences, said the finding challenges ...
... field of golden-flowered stems swaying in an autumn breeze ... serious battles between natural enemies that took place in ... to attack by several species of insects that lay ... that can reduce or even completely prevent goldenrod from ...
... arsenal against cancer: Nanoparticles that identify, target and kill ... Led by Carl Batt, the Liberty Hyde Bailey Professor ... something like a dumbbell made of gold sandwiched ... antibodies, which target a molecule found only in colorectal ...
Cached Biology News:Intentional variation increases result validity in mouse testing 2Intentional variation increases result validity in mouse testing 3What should goldenrod do to avoid an insect attack? Duck 2What should goldenrod do to avoid an insect attack? Duck 3Like little golden assassins, 'smart' nanoparticles identify, target and kill cancer cells 2
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
... Zeba Desalt Spin Columns contain a ... that offers exceptional desalting and protein-recovery characteristics ... containing as low as 25 g/ml of ... recovery and > 95% retention of salts ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
... Synthetic peptide corresponding to ... Antigen Family: Regulator ... Subfamily: not assigned-Regulator ... Storage: Long term: ...
Biology Products: